Orthofix Raises 2026 Guidance After Q2 Sales Beat, Medicare Headwind Removed
OFIX sits 51% above its 52-week low of $8.85.
Summary
Orthofix delivered Q2 net sales of $210.9M, up 5% pro forma constant currency, and raised full-year 2026 guidance for both net sales and adjusted EBITDA. The quarter saw double-digit growth in Global Spine Fixation and Limb Reconstruction, while Therapeutic Solutions grew 3% despite a temporary Medicare reimbursement headwind that has since been reversed. Adjusted EBITDA came in at $20.1M, roughly flat year-over-year, but the raised outlook signals management confidence in accelerating momentum. This follows the July CMS reversal that restored bone growth stimulator reimbursement, removing a key overhang. With Biologics stabilizing and commercial execution improving, the second half setup looks materially stronger than the first.
At the time of this announcement, OFIX was trading at $13.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $493.1M. The 52-week trading range was $8.85 to $16.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.